AstraZeneca PLC - American Depositary Shares (NY:AZN)

Topics ETFs

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗

May 02, 2026

This pharma stock is cheap for a reason.

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth ↗

Topics Intellectual Property

April 24, 2026

Via Chartmill

Pictet Loads Up MercadoLibre With 3,500 Shares Worth $6.8 Million ↗

April 14, 2026

MercadoLibre powers e-commerce, payments, and logistics for millions in Latin America with its integrated digital platform.

AbbVie is making progress in this market, but it is still far behind the leader.

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

Topics Economy

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

Topics Bonds

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

Topics Economy Government Lawsuit

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Topics Intellectual Property

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Topics ETFs Intellectual Property Stocks

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

Via Finterra

Topics Initial Public Offering

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

Topics Intellectual Property

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way...

International stocks look attractively valued in an expensive market environment.

Topics Artificial Intelligence Economy

Could This International ETF Be One of the Best Investments of 2026? ↗

March 14, 2026

The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis

Topics ETFs

March 13, 2026

In the high-stakes theater of corporate earnings calls, a "beat" on the bottom line used to be a guaranteed ticket to a stock price rally. However, as we move through the first quarter of 2026, a new...

The opening months of 2026 have revealed a startling paradox in the global financial landscape: while the sheer number of corporate marriages is dwindling, the price tags on the few remaining...

Topics Artificial Intelligence Earnings Regulatory Compliance

The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026

March 11, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Topics Artificial Intelligence Economy Energy

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

Via Finterra

Topics Economy Intellectual Property Lawsuit

The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026

March 05, 2026

As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international...

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Topics Artificial Intelligence ETFs Economy

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Topics Earnings

As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗

March 02, 2026

Topics ETFs

After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗

February 27, 2026

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

Topics Artificial Intelligence

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange

Topics Economy Intellectual Property

February 26, 2026

On February 2, 2026, AstraZeneca PLC (NYSE: AZN) officially rang the opening bell at the New York Stock Exchange, marking the completion of its high-profile transition from the Nasdaq. The move signals...

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

Topics ETFs

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Topics Intellectual Property

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

Topics Intellectual Property

February 16, 2026

Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade.

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

Topics ETFs Stocks

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...

Topics Artificial Intelligence Economy Intellectual Property

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗

February 12, 2026